Among the different ancillary immunohistochemical tools that pathologists may employ in thyroid nodules, the so-called Hector Battifora's 'MEsothelioma' 1 (HBME-1) staining is one of the most fascinating, since its real identity is currently unknown. In the present review, the different clinical applications of HBME-1 are analysed, with main emphasis on its role in thyroid pathology with overview on less impactful fields, such as haematopathology or mesothelial lesions. Different acceptable or good diagnostic performances were recorded for HBME-1 in thyroid pathology, being used in routine practice as one of the best tools to screen thyroid malignancy both in terms of sensitivity and specificity. From a speculative point of view, after many attempts to hunt the cryptic target antigen of this antibody, its identity still remains elusive. In this setting, the application of high-throughput technologies (mainly in situ proteomics) may be the exact route to improve the knowledge about the pathophysiology of HBME-1 and to finally unveil its true identity.

Cazzaniga, G., Seminati, D., Smith, A., Piga, I., Capitoli, G., Garancini, M., et al. (2022). Lights on HBME-1: the elusive biomarker in thyroid cancer pathology. JOURNAL OF CLINICAL PATHOLOGY [10.1136/jclinpath-2022-208248].

Lights on HBME-1: the elusive biomarker in thyroid cancer pathology

Cazzaniga, Giorgio
;
Seminati, Davide;Smith, Andrew;Piga, Isabella;Capitoli, Giulia;Garancini, Mattia;L'Imperio, Vincenzo;Pagni, Fabio
2022

Abstract

Among the different ancillary immunohistochemical tools that pathologists may employ in thyroid nodules, the so-called Hector Battifora's 'MEsothelioma' 1 (HBME-1) staining is one of the most fascinating, since its real identity is currently unknown. In the present review, the different clinical applications of HBME-1 are analysed, with main emphasis on its role in thyroid pathology with overview on less impactful fields, such as haematopathology or mesothelial lesions. Different acceptable or good diagnostic performances were recorded for HBME-1 in thyroid pathology, being used in routine practice as one of the best tools to screen thyroid malignancy both in terms of sensitivity and specificity. From a speculative point of view, after many attempts to hunt the cryptic target antigen of this antibody, its identity still remains elusive. In this setting, the application of high-throughput technologies (mainly in situ proteomics) may be the exact route to improve the knowledge about the pathophysiology of HBME-1 and to finally unveil its true identity.
Articolo in rivista - Review Essay
Scientifica
cell differentiation; immunohistochemistry; thyroid cancer;
English
Cazzaniga, G., Seminati, D., Smith, A., Piga, I., Capitoli, G., Garancini, M., et al. (2022). Lights on HBME-1: the elusive biomarker in thyroid cancer pathology. JOURNAL OF CLINICAL PATHOLOGY [10.1136/jclinpath-2022-208248].
Cazzaniga, G; Seminati, D; Smith, A; Piga, I; Capitoli, G; Garancini, M; L'Imperio, V; Fusco, N; Pagni, F
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/369995
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact